IMV
IMV is a Canadian biopharmaceutical company focused on developing immunotherapies for serious human diseases using its proprietary lipid-based delivery system, which the company calls DPX.
3
Funding Rounds
$55.3m
Money raised
Overview
IMV is a Canadian biopharmaceutical company focused on developing immunotherapies for serious human diseases using its proprietary lipid-based delivery system, which the company calls DPX.
-
Website:
- Business model: B2B
- Headquarters: New Canada, Nova Scotia
- Social accounts:
Funding
Funding series
Funding Series Analysis
The company IMV has raised a total of $55.35m in funding over 3 rounds.
Key Insights:
- IMV Funding Round, January 2022: $750k
- IMV Private equity, May 2020: $25.1m
- IMV Private equity, March 2019: $29.5m
IMV Funding Round, January 2022
$750k
IMV Private equity, May 2020
$25.1m
IMV Private equity, March 2019
$29.5m
Industries
IMV is active in the following industries: